Trial Profile
A Randomized, Double-Blind, Crossover Study Comparing the Safety and Tolerability of Two Dose Regimens of Oromucosal Fipamezole ODT in Adult Patients With Parkinson's Disease Who Are Receiving Levodopa.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 16 May 2019
Price :
$35
*
At a glance
- Drugs Fipamezole (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Bausch Health Companies
- 13 Jul 2018 According to a Bausch Health Companies media release, Valeant Pharmaceuticals International changed its name to Bausch Health Companies.
- 21 Jun 2012 Additional lead trial investigator (Ralph T. Doyle) identified as reported by ClinicalTrials.gov.
- 29 Nov 2010 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.